Elevated AST or ALT to nonalcoholic fatty liver disease: Accurate predictor of disease prevalence?

American Journal of Gastroenterology

Volumn 98, Issue 5, 2003, Pages 955-956

  Yu, Andy S ^a,b   Keeffe, Emmet B ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC LIVER DISEASE; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE MARKER; EDITORIAL; FATTY LIVER; HUMAN; LIVER CIRRHOSIS; OBESITY; PREVALENCE; PRIORITY JOURNAL;

EID: 0037733958     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2003.07485.x     Document Type: Editorial

References (20)

1. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferease levels in the United States. Am J Gastroenterol 2003;98:960-967.
2. Green RM, Flamm S. AGA technical review on the evaluation of liver chemistry tests. Gastroenterology 2002;123:1367-84.
3. Armstrong GL, Alter MJ, McQuillan GM, et al. The past incidence of hepatitis C virus infection: Implications for the future burden of chronic liver disease in the United States. Hepatology 2000;31:777-82.
4. Kim WR, Brown RS Jr, Terrault NA, et al. Burden of liver disease in the United States: Summary of a workshop. Hepatology 2002;36:227-42.
5. Grant BG, Harford TC, Dawson DA, et al. Prevalence of DSMIV alcohol abuse and dependence in United States 1992. Alcohol Health Res World 1994;18:243-8.
6. Powell LW, George DK, McDonnell SM, et al. Diagnosis of hemochromatosis. Ann Intern Med 1998;129:925-31.
7. Boberg KM, Aadland E, Jahnsen J, et al. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 1998;33:99-103.
8. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-9.
9. Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999;107:450-5.
10. Yu AS, Keeffe EB. Nonalcoholic fatty liver disease. Rev Gastroenterol Disord 2002;2:11-9.
11. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. J Am Med Assoc 2003;289:76-9.
12. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors. Hepatology 1990;12:1106-10.
13. Clain DJ, Lefkowitch JH. Fatty liver disease in morbid obesity. Gastroenterol Clin North Am 1987;16:239-52.
14. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2003;124:71-9.
15. Clark JM, Diehl AM. Defining nonalcoholic fatty liver disease: Implications for epidemiologic studies. Gastroenterology 2003;124:248-50 (editorial).
16. Caldwell SH, Oelsner DH, Iezzoni JC, et al. Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease. Hepatology 1999;29:664-9.
17. Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: A case-control study. Hepatology 2000;32:689-92.
18. Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002;123:134-40.
19. Ong J, Younossi ZM, Reddy V, et al. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl 2001;7:797-801.
20. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002;137:1-10.